Thalassemia major and sickle cell disease are the two most widely disseminated hereditary hemoglobinopathies in the world. The outlook for affected individuals has improved in recent years due to advances in medical management in the prevention and treatment of complications. However, hematopoietic stem cell transplantation is still the only available curative option. The use of hematopoietic stem cell transplantation has been increasing, and outcomes today have substantially improved compared with the past three decades. Current experience world-wide is that more than 90% of patients now survive hematopoietic stem cell transplantation and disease-free survival is around 80%. However, only a few controlled trials have been reported, and decisions on patient selection for hematopoietic stem cell transplantation and transplant management remain principally dependent on data from retrospective analyses and on the clinical experience of the transplant centers. This consensus document from the European Blood and Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party aims to report new data and provide consensus-based recommendations on indications for hematopoietic stem cell transplantation and transplant management. © 2014 by the Ferrata Storti Foundation.

Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel / E. Angelucci, S. Matthes-Martin, D. Baronciani, F. Bernaudin, S. Bonanomi, M.D. Cappellini, J. Dalle, P. Di Bartolomeo, C.D. de Heredia, R. Dickerhoff, C. Giardini, E. Gluckman, A.A. Hussein, N. Kamani, M. Minkov, F. Locatelli, V. Rocha, P. Sedlacek, F. Smiers, I. Thuret, I. Yaniv, M. Cavazzana, C. Peters. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 99:5(2014), pp. 811-820.

Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel

M.D. Cappellini;
2014

Abstract

Thalassemia major and sickle cell disease are the two most widely disseminated hereditary hemoglobinopathies in the world. The outlook for affected individuals has improved in recent years due to advances in medical management in the prevention and treatment of complications. However, hematopoietic stem cell transplantation is still the only available curative option. The use of hematopoietic stem cell transplantation has been increasing, and outcomes today have substantially improved compared with the past three decades. Current experience world-wide is that more than 90% of patients now survive hematopoietic stem cell transplantation and disease-free survival is around 80%. However, only a few controlled trials have been reported, and decisions on patient selection for hematopoietic stem cell transplantation and transplant management remain principally dependent on data from retrospective analyses and on the clinical experience of the transplant centers. This consensus document from the European Blood and Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party aims to report new data and provide consensus-based recommendations on indications for hematopoietic stem cell transplantation and transplant management. © 2014 by the Ferrata Storti Foundation.
Hematology
Settore MED/09 - Medicina Interna
http://www.haematologica.org/content/99/5/811.full.pdf
Article (author)
File in questo prodotto:
File Dimensione Formato  
811.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 274.13 kB
Formato Adobe PDF
274.13 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/248416
Citazioni
  • ???jsp.display-item.citation.pmc??? 95
  • Scopus 245
  • ???jsp.display-item.citation.isi??? 224
social impact